HPV+ HNSCC patients with tumours exhibiting low SDHC expression had better overall five-year survival outcomes than HPV+ HNSCC patients with tumours exhibiting high SDHC expression (p = 0.011, FDR = 0.043) (Figure 2B). The gene discussed is SDHC; the disease is neoplasm.